Hospitals that enrolled in the 340B program after its expansion in 2010 treated more commercially insured cancer patients with five commonly prescribed biologic oncology drugs and spent more on the drugs, a new JAMA study found.
The authors of
Articles by : William Newton, Associate Editor/Senior Writer
What do the outcomes of 340B policy debates in two state legislatures on opposite ends of the political spectrum mean for 340B stakeholders? 340B Report Publisher and CEO Ted Slafsky gives the most important takeaways in his latest column for
…
Minnesota health care providers were shocked to learn that a bill signed into law in late May made their state the first to require all 340B covered entities to report their total 340B drug acquisition costs and payments.
The first
…
The American Hospital Association has asked the U.S. Health Resources and Services Administration to resume letting hospitals dispense 340B drugs at offsite clinics that have not yet appeared on the hospital’s most recently filed Medicare cost report.
AHA asked HRSA
…